Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing database survey of shock and anaphylaxis after Spykevax monovalent Original vaccination in high-risk patients
jRCT2031220747Active, not recruiting
- Sponsor
- Moderna Inc
- Start
- Jan 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of elasomeran in coronavirus disease 2019 (COVID-19), sponsored by Moderna Inc. Primary endpoint: Primary incidence of hypersensitivity reactions within 2 days after vaccination. Started Jan 2023; status: active, not recruiting.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031220747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220747.